Very low-dose skin radiation for mycosis fungoides spots
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether ultra low-dose radiation can control specific skin lesions from mycosis fungoides (a type of lymphoma that affects the skin). It may help shrink or control targeted spots while using a lower radiation amount.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mycosis fungoides that has been confirmed by a pathology (biopsy) report and affects your skin
- You have at least one measurable skin lesion the team can see and measure on a physical exam
- The specific spot being treated must be small: 1 cm tall or less from the skin surface
- The trial can include many disease stages if radiation is being considered for local control of the spot
- If you could become pregnant, you must have a negative pregnancy test before starting treatment
- You cannot have active lupus or scleroderma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This Phase 3 study tests a low-dose skin radiation treatment (electron beam) to help eradicate the harmful cancer cells in early-stage mycosis fungoides. It may be an option if you have stage IB or IIA disease and can safely undergo the required light/radiation preparation steps.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study tests a new drug called VG712 in patients with mycosis fungoides, a rare type of skin lymphoma that hasn't responded to previous treatments. The goal is to see if VG712 can shrink the cancer and improve quality of life.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.